Cytokinetics (CYTK) Invested Capital (2016 - 2025)
Historic Invested Capital for Cytokinetics (CYTK) over the last 15 years, with Q3 2024 value amounting to $547.2 million.
- Cytokinetics' Invested Capital rose 44073.85% to $547.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $547.2 million, marking a year-over-year increase of 44073.85%. This contributed to the annual value of $174.8 million for FY2023, which is 6143.06% down from last year.
- Cytokinetics' Invested Capital amounted to $547.2 million in Q3 2024, which was up 44073.85% from $669.7 million recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Invested Capital ranged from a high of $669.7 million in Q2 2024 and a low of -$78.1 million during Q2 2020
- In the last 5 years, Cytokinetics' Invested Capital had a median value of $206.9 million in 2023 and averaged $252.0 million.
- Over the last 5 years, Cytokinetics' Invested Capital had its largest YoY gain of 113669.2% in 2020, and its largest YoY loss of 149477.12% in 2020.
- Cytokinetics' Invested Capital (Quarter) stood at $113.4 million in 2020, then skyrocketed by 115.08% to $243.9 million in 2021, then surged by 85.86% to $453.2 million in 2022, then tumbled by 61.43% to $174.8 million in 2023, then soared by 213.04% to $547.2 million in 2024.
- Its Invested Capital was $547.2 million in Q3 2024, compared to $669.7 million in Q2 2024 and $165.0 million in Q1 2024.